Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

被引:3
|
作者
Bhasin, Satyam [1 ,2 ]
Dusek, Christopher [1 ,2 ]
Peacock, James W. [1 ,2 ]
Cherkasov, Artem [1 ,2 ]
Wang, Yuzhuo [1 ,2 ]
Gleave, Martin [1 ,2 ]
Ong, Christopher J. [1 ,2 ]
机构
[1] Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
[2] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada
关键词
ER+ breast cancer; Semaphorin; 3C; plexin-B1; siRNA knockdown; Akt-MAPK signaling; apoptosis; B1SP; tamoxifen-resistance; EXPRESSION; MECHANISMS; IMPACT;
D O I
10.3390/cells12131715
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Estrogen receptor positive (ER+) breast cancer (BCa) accounts for the highest proportion of breast cancer-related deaths. While endocrine therapy is highly effective for this subpopulation, endocrine resistance remains a major challenge and the identification of novel targets is urgently needed. Previously, we have shown that Semaphorin 3C (SEMA3C) is an autocrine growth factor that drives the growth and treatment resistance of various cancers, but its role in breast cancer progression and endocrine resistance is poorly understood. Here, we report that SEMA3C plays a role in maintaining the growth of ER+ BCa cells and is a novel, tractable therapeutic target for the treatment of ER+ BCa patients. Analyses of publicly available clinical datasets indicate that ER+ BCa patients express significantly higher levels of SEMA3C mRNA than other subtypes. Furthermore, SEMA3C mRNA expression was positively correlated with ESR1 mRNA expression. ER+ BCa cell lines (MCF7 and T47D) expressed higher levels of SEMA3C mRNA and protein than a normal mammary epithelial MCF10A cell line. ER siRNA knockdown was suppressed, while dose-dependent beta-estradiol treatment induced SEMA3C expression in both MCF7 and T47D cells, suggesting that SEMA3C is an ER-regulated gene. The stimulation of ER+ BCa cells with recombinant SEMA3C activated MAPK and AKT signaling in a dose-dependent manner. Conversely, SEMA3C silencing inhibited Estrogen Receptor (ER) expression, MAPK and AKT signaling pathways while simultaneously inducing apoptosis, as monitored by flow cytometry and Western blot analyses. SEMA3C silencing significantly inhibited the growth of ER+ BCa cells, implicating a growth dependency of ER+ BCa cells on SEMA3C. Moreover, the analysis of tamoxifen resistant (TamR) cell models (TamC3 and TamR3) showed that SEMA3C levels remain high despite treatment with tamoxifen. Tamoxifen-resistant cells remained dependent on SEMA3C for growth and survival. Treatment with B1SP Fc fusion protein, a SEMA3C pathway inhibitor, attenuated SEMA3C-induced signaling and growth across a panel of tamoxifen sensitive and resistant ER+ breast cancer cells. Furthermore, SEMA3C silencing and B1SP treatment were associated with decreased EGFR signaling in TamR cells. Here, our study implicates SEMA3C in a functional role in ER+ breast cancer signaling and growth that suggests ER+ BCa patients may benefit from SEMA3C-targeted therapy.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression
    Peng, Hao
    Yang, Meng
    Feng, Kun
    Lv, Qingpeng
    Zhang, Yewei
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [2] A Pilot Study of the Role of Semaphorin 4A (sema4A) and 3C (sema3C) in Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Purpurowicz, Piotr
    Kaminski, Tomasz W.
    Kordan, Wladyslaw
    Korzekwa, Anna
    Purpurowicz, Zbigniew
    Jablonowski, Zbigniew
    BIOMEDICINES, 2024, 12 (10)
  • [3] A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization
    Toledano, Shire
    Lu, Huayi
    Palacio, Agustina
    Ziv, Keren
    Kessler, Ofra
    Schaal, Shlomit
    Neufeld, Gera
    Barak, Yoreh
    PLOS ONE, 2016, 11 (12):
  • [4] SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis
    Liu, Ruoyan
    Shuai, Yanjie
    Luo, Jingtao
    Zhang, Ze
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [5] Expression of Semaphorin 3C in Breast Cancer and its Impact on Adhesion and Invasion of Breast Cancer Cells
    Malik, Muhammad Faraz Arshad
    Satherley, Lucy K.
    Davies, Eleri L.
    Ye, Lin
    Jiang, Wen G.
    ANTICANCER RESEARCH, 2016, 36 (03) : 1281 - 1286
  • [6] Semaphorin 3C is involved in the progression of gastric cancer
    Miyato, Hideyo
    Tsuno, Nelson Hirokazu
    Kitayama, Joji
    CANCER SCIENCE, 2012, 103 (11) : 1961 - 1966
  • [7] SEMA3C promotes thyroid cancer via the Wnt/(3-catenin pathway
    Li, Shiwei
    Cheng, Yanmei
    Gao, Changhui
    Yuan, Qingling
    Lu, Xiubo
    EXPERIMENTAL CELL RESEARCH, 2025, 444 (02)
  • [8] THE ROLE OF SEMAPHORIN-3C (SEMA3C) IN INTERPLAY BETWEEN RENAL EPITHELIAL-ENDOTHELIAL CELLS DURING CYST DEVELOPMENT IN POLYCYSTIC KIDNEY DISEASE
    Park, J.
    Lee, E.
    CARDIOLOGY, 2018, 140 : 156 - 156
  • [9] SEMAPHORIN 3C PROMOTES SURVIVAL SIGNALING AND CASTRATION RESISTANT PROGRESSION IN PROSTATE CANCER
    Hayashi, Norihiro
    Shiota, Masaki
    Kuruma, Hidetoshi
    Egawa, Shin
    Ong, Christopher
    Gleave, Martin
    JOURNAL OF UROLOGY, 2012, 187 (04): : E395 - E395
  • [10] Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells
    Yenki, Parvin
    Bhasin, Satyam
    Liu, Liang
    Nabavi, Noushin
    Cheng, Chi Wing
    Tam, Kevin J.
    Peacock, James W.
    Adomat, Hans H.
    Tombe, Tabitha
    Fazli, Ladan
    Ivanova, Larissa
    Dusek, Christopher
    Khosravi, Shahram
    Guns, Emma S. Tomlinson
    Wang, Yuzhuo
    Buttyan, Ralph
    Gleave, Martin E.
    Ong, Christopher J.
    ENDOCRINE-RELATED CANCER, 2023, 30 (12)